Article Text

Download PDFPDF
Best original research presented at the 25th European Congress on Gynaecological Oncology: best of ESGO 2024
    1. 1 II Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland
    2. 2 Cancer Prevention Department, Center de Lutte Contre le Cancer Léon Bérard, Lyon, France
    3. 3 UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
    4. 4 Department of Obstetrics and Gynecology, University Hospital Schleswig-Holstein-Campus Kiel, Kiel, Germany
    5. 5 Department of Global Health, Koç University Graduate School of Health Sciences, Istanbul, Turkey
    6. 6 Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    7. 7 Gynecological Cancer Center, University Hospital Basel, Basel, Switzerland
    8. 8 Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen Mitte, Essen, Germany
    9. 9 Department of Obstetrics and Gynecology, JW Goethe Frankfurt University, Frankfurt am Main, Germany
    10. 10 Gynecologic Oncology Unit, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
    11. 11 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California, USA
    12. 12 Department of Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany
    13. 13 Division of Gynecologic Oncology, 1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens School of Health Sciences, Athens, Greece
    14. 14 Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary
    15. 15 Department of Gynecology, University Hospital of Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
    16. 16 Gynecology and Obstetrics Department, Clinica Universidad de Navarra, Pamplona, Spain
    17. 17 Humanitas San Pio X Milan, Humanitas University Pieve Emanuele, Milan, Italy
    1. Correspondence to Dr Joanna Kacperczyk-Bartnik, II Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, 00-315, Poland; asiakacperczyk{at}gmail.com

    Abstract

    The 'Best of ESGO 2024' article includes a selection of the most highly rated original research presented during the 25th Annual Congress of the European Society of Gynaecologic Oncology (ESGO), held in Barcelona, Spain, March 7–10, 2024. Of 1218 asbtracts submitted, 35 studies presented during the best oral sessions, mini oral sessions, best three minute presentations session, and young investigator session were selected by the ESGO abstract committee and the authors of the European Network of Young Gynae Oncologists (ENYGO). There was a strong focus on the surgical treatment of early stage cervical cancer and the management of advanced or recurrent gynecological cancers using induction therapy, immunotherapy, and maintenance therapy. With this work, ENYGO and ESGO aim to focus the attention of clinicians, scientists, patients, and all stakeholders interested in gynecologic oncology on research advances in the field.

    • Cervical Cancer
    • Ovarian Cancer
    • Uterine Cancer

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • X @Joanna86992517, @housseinelhajj3, @esragbilir, @aStrojnaMD, @AngelesFite

    • Contributors All authors contributed to the preparation of the manuscript. Data collection and manuscript preparation: JK-B, HEH, NB, EB, TAZ, ANS, KG, MAA, VG, HE, TN, CT, and RT. Project administration and preparation of the original draft: JK-B. Supervision and critical revisions: JPS, LC, and DL.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.